Nasal spray may reduce breathing risks during ERCP
NCT ID NCT07204106
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a dexmedetomidine nasal spray to the usual sedative propofol could reduce breathing problems during ERCP, a procedure to treat bile duct issues. 180 adults were split into three groups: one got the nasal spray plus propofol, another got dexmedetomidine through an IV plus propofol, and the third got propofol alone. The main goal was to see if the nasal spray lowered the chance of low blood oxygen levels during the procedure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dexmedetomidine nasal spray
- What this could lead to
- If it works, this could offer a safer sedation method for ERCP with fewer breathing issues.
- What could go wrong
- This is a small, completed study. Results may not apply to all patients, and side effects like low blood pressure or slow heart rate are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
180 people
The number who actually took part.
- Started
-
Oct 2025
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * no restriction on gender, * aged 18-70 years, * BMI of 18-30 kg/m², * American Society of Anesthesiologists (ASA) physical status Ⅰ or Ⅱ. Exclusion Criteria: * Patients who explicitly refused to participate in the study; * Patients with difficult airway management (modified Mallampati score of Grade IV); * Patients with anemia or thrombocytopenia (Hb \< 90 g/L, PLT \< 80×10⁹/L); * Patients with abnormal liver or kidney function; * Patients with a history of nasal surgery/trauma or deviated nasal septum; * Patients with allergies or contraindications to dexmedetomidine, opioids, propofol, rocuronium, or their components; * Patients with a history of abnormal recovery from previous surgery or anesthesia.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dexmedetomidine induced sedation are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital,Affiliated to Tongji University
Shanghai, Shanghai Municipality, 200120, China